<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10115">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690495</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-0705</org_study_id>
    <nct_id>NCT00690495</nct_id>
  </id_info>
  <brief_title>Use of a Modified Propofol Emulsion in Adults</brief_title>
  <official_title>Prospective, Monocentric Controlled, Randomized, Double-blind Study to Compare the Two Different Propofol Emulsions Regarding Tolerability and Injection Pain During the Induction of Anesthesia in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether a modified propofol preparation shows any
      effect on the incidence of injection pain in adults undergoing elective surgery under
      general anesthesia.

      Study hypothesis: The use of a modified propofol preparation will reduce the incidence of
      injection pain in the study group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain on injection is a most frequently reported side effect associated with the use of
      propofol for induction of anesthesia. Various measures have been taken to reduce the pain on
      injection, e.g. administration of lidocaine or fentanyl prior to propofol administration,
      mixture of lidocaine and propofol as well as cooling of the emulsion. Although pain on
      injection had been reduced with some of the above mentioned methods, they may not be
      regarded as a satisfactory solution of the problem.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of Expression of Pain During Injection</measure>
    <time_frame>during first propofol bolus</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Further Assessment of Injection Pain</measure>
    <time_frame>during induction of anaesthesia and about 3 to 6 hours after end of anaesthesia</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified propofol (Propofol 0.5%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol 1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol (drug), intravenous, induction of anesthesia</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Modified propofol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol 1%</intervention_name>
    <description>Propofol (drug), intravenous, induction of anesthesia</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Propofol-Lipuro 1%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults, age ≥ 18 years and ≤ 80 years

          -  Anesthetic risk classified as ASA I-III

          -  Patients undergoing elective surgery under general anesthesia

          -  Signed informed consent

        Exclusion Criteria:

          -  Simultaneous participation in another trial

          -  Known or suspected drug abuse

          -  Known hypersensitivity to Propofol, other ingredients of the emulsion, or to any
             other necessary co-medication

          -  Not allowed concomitant medication (psychopharmacologic agents, tranquilizers, or
             centrally active analgesics)

          -  Patients taking lipid lowering drugs

          -  History of decompensated renal failure

          -  History of severe hepatic dysfunction, hepatic cirrhosis

          -  Angiographically confirmed CHD (coronary heart disease) or cerebral ischemia

          -  History of convulsive disorders

          -  Decompensated cardiac insufficiency

          -  Hypovolemia

          -  Increased intracranial pressure

          -  Pregnancy (positive ß-HCG test) and lactation

          -  Emergency situation

          -  Patient who receives parenteral fat emulsion, e.g. intralipid

          -  Patients incapable of giving consent personally

          -  Venous access for induction of anesthesia not possible at dorsum of the hand or not
             dorsal
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Soltész, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Anästhesie und operative Intensivmedizin, Klinikum Leverkusen gGmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Anästhesie und operative Intensivmedizin, Klinikum Leverkusen gGmbH</name>
      <address>
        <city>Leverkusen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>January 2, 2012</lastchanged_date>
  <firstreceived_date>June 2, 2008</firstreceived_date>
  <firstreceived_results_date>August 17, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>Induction</keyword>
  <keyword>Pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient in: 07.05.2008 Last patient out: 24.09.2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Modified Propofol</title>
          <description>Modified propofol (Propofol 0.5%)</description>
        </group>
        <group group_id="P2">
          <title>Propofol 1%</title>
          <description>Propofol 1%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Primary Endpoint</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modified Propofol</title>
          <description>Modified propofol (Propofol 0.5%)</description>
        </group>
        <group group_id="B2">
          <title>Propofol 1%</title>
          <description>Propofol 1%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
                <measurement group_id="B2" value="50"/>
                <measurement group_id="B3" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="68"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54.4" spread="14.6"/>
                <measurement group_id="B2" value="55.2" spread="13.9"/>
                <measurement group_id="B3" value="54.8" spread="14.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="74"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
                <measurement group_id="B2" value="50"/>
                <measurement group_id="B3" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Expression of Pain During Injection</title>
        <time_frame>during first propofol bolus</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Propofol</title>
            <description>Modified propofol (Propofol 0.5%)</description>
          </group>
          <group group_id="O2">
            <title>Propofol 1%</title>
            <description>Propofol 1%</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Expression of Pain During Injection</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Further Assessment of Injection Pain</title>
        <time_frame>during induction of anaesthesia and about 3 to 6 hours after end of anaesthesia</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Modified Propofol</title>
          <description>Modified propofol (Propofol 0.5%)</description>
        </group>
        <group group_id="E2">
          <title>Propofol 1%</title>
          <description>Propofol 1%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="50"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study manager</name_or_title>
      <organization>B.Braun Melsungen AG</organization>
      <phone>+49 5661 71 ext 0</phone>
      <email>studies@bbraun.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
